SESSION TITLE: Lung Cancer II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: It has been shown that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) can decrease tumor growth and tumor-associated angiogenesis and inhibit metastasis. In approximately 30% of patients with advanced non-small-cell lung cancer (NSCLC) in East Asia and in 10-15% of patients from Western countries, epidermal growth factor receptor (EGFR) mutations are found.